Pyridoxine
- Generic Name
- Pyridoxine
- Brand Names
- Alertonic, Animi-3 With Vitamin D, Bonjesta, Citranatal B-calm Kit, Citranatal Harmony, Concept Ob, Diclectin, Diclegis, Folbic, Foltabs, Fortaplex, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Isotamine B, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Pregvit, Tandem Plus, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11NO3
- CAS Number
- 65-23-6
- Unique Ingredient Identifier
- KV2JZ1BI6Z
- Background
Pyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. As its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for normal functioning of many biological systems within the body. While many plants and microorganisms are able to synthesize pyr...
- Indication
Pyridoxine is indicated for the treatment of vitamin B6 deficiency and for the prophylaxis of Isoniazid-induced peripheral neuropathy. It is also approved by Health Canada for the treatment of nausea and vomiting in pregnancy in a combination product with Doxylamine (as the commercially available product Diclectin).
- Associated Conditions
- Back pain, Dizziness, Fever, Headache, Hepatic; Functional Disturbance, Hepatitis, Iron Deficiency Anemia (IDA), Ketosis, Macrocytic anemia, Menière's Disease, Menstrual Distress (Dysmenorrhea), Metabolic Acidosis, Motion Sickness, Myalgia, Nausea and vomiting, Neuralgia, Sciatic, Neuritis, Neurological Conditions caused by B Vitamin Deficiency, Secondary anemia, Toothache, Toxinfectious state, Trigeminal Neuralgia (TN), Vitamin B1 deficiency, Vitamin B12 Deficiency, Vitamin B6 Deficiency, Vitamin Deficiency, Minor aches and pains, Minor pain
- Associated Therapies
- Nutritional supplementation, Supplementation, Vitamin supplementation, Wellness of the Liver
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 525
- Registration Number
- NCT00000796
- Locations
- 🇺🇸
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Bronx Lebanon Hosp Ctr, Bronx, New York, United States
Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 50
- Registration Number
- NCT00000950
- Locations
- 🇺🇸
Emory Univ, Atlanta, Georgia, United States
🇺🇸Beth Israel Med Ctr, New York, New York, United States
🇺🇸Queens Med Ctr, Honolulu, Hawaii, United States
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-08
- Target Recruit Count
- 44
- Registration Number
- NCT00000778
- Locations
- 🇺🇸
Tulane Univ Med School, New Orleans, Louisiana, United States
🇺🇸UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Harbor - UCLA Med Ctr, Torrance, California, United States
Vitamin Therapy for Prevention of Stroke
- Conditions
- Locations
- 🇺🇸
Wake Forest University School of Medicine, Winston Salem, North Carolina, United States
Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 30
- Registration Number
- NCT00004758
Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 84
- Registration Number
- NCT00004495
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.